| 產(chǎn)品編號 | BIO0997SM |
| 英文名稱(chēng) | Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab Biosimilar) |
| 中文名稱(chēng) | |
| 別 名 | TNFRSF9 / 4-1BB / CD137 & B7-H1 / PD-L1 / CD274; Acasunlimab |
| 抗體來(lái)源 | |
| 克隆類(lèi)型 | Monoclonal |
| 克 隆 號 | |
| 交叉反應 | Human |
| 產(chǎn)品應用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 144.08 kDa |
| 檢測分子量 | |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Acasunlimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Acasunlimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 1.875 nM.
Co-incubation of Acasunlimab with 4-1BB-NF-κB-Jurkat cells, then with the addition of huPD-L1-CHO-K cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Acasunlimab was able to activate the NF-κB signaling pathway, and the EC50 was 0.341 nM.
Acasunlimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Acasunlimab bound to huPD-L1-CHO-K cells, and the EC50 was 1.153 nM.
Acasunlimab bound to hu4-1BB-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Acasunlimab bound to hu4-1BB-CHO-K cells, and the EC50 was 3.592 nM.
To measure the binding ability of Acasunlimab in hu-PD-L1-His. Acasunlimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Acasunlimab bound to hu-PD-L1-His, and the EC50 was 0.042 nM.
To measure the binding ability of Acasunlimab in hu-4-1BB-His. Acasunlimab bound to 4-1BB protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Acasunlimab bound to hu-4-1BB-His, and the EC50 was 0.007 nM.
The purity of Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab) is 94.41%, determined by SEC-HPLC.
Anti-4-1BB & PD-L1 Reference Antibody (Acasunlimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
